ArticleTobacco prevention & cessation2022
Anticipating IQOS market expansion in the United States.
Article in Tobacco prevention & cessation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Evidence-based practices are effective in increasing smoke-free home rules among Black women who smoke.Journal of the National Cancer Institute. Monographs · 2025Trial
- The use of interactive and engaging events in Austin, Texas, to promote the US return of IQOS.Tobacco prevention & cessation · 2026Article
- Effects of Emissions from Heated Tobacco Products and Reference Cigarettes on Gene Expression and Mitochondrial Function in Human Lung Epithelial BEAS-2B CellsAntioxidants (Basel, Switzerland) · 2025Article
- Large Language Models' Accuracy in Emulating Human Experts' Evaluation of Public Sentiments about Heated Tobacco Products on Social Media: Evaluation Study.Journal of medical Internet research · 2025Article
- Perceptions of Heated Tobacco Products (HTPs) Versus Cigarettes and e-Cigarettes in Relation to Likelihood of Trying HTPs or Suggesting HTPs to Those who Smoke Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024Article
- Impact of smoking intensity and device cleaning on IQOS emissions: comparison with an array of cigarettes.Tobacco control · 2024Article
- IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.Tobacco control · 2024Article
- Nicotine pouch marketing strategies in the USA: an analysis of Zyn, On! and Velo.Tobacco control · 2024Article
- Impact of exposures to Heated Tobacco Products in the media and through social connections on product perceptions and use.Tobacco prevention & cessation · 2024Article
- A scoping review of the toxicity and health impact of IQOS.Tobacco induced diseases · 2024Article
- Health warning labels on heated tobacco products and their impact on use intentions and risk perceptions: a cross-sectional study of adult tobacco users in the US and Israel.Israel journal of health policy research · 2023Article
- Heated Tobacco Products: Awareness, Beliefs, Use and Susceptibility among US Adult Current Tobacco Users, 2021.International journal of environmental research and public health · 2023Article
- Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.Frontiers in public health · 2023Article
- A Decision-Theoretic Public Health Framework for Heated Tobacco and Nicotine Vaping Products.International journal of environmental research and public health · 2022Article
- 'It's like if a vape pen and a cigarette had a baby': a mixed methods study of perceptions and use of IQOS among US young adults.Health education research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
IQOS is sold globally in over 60 countries and entered the US market in 2019 and by 17 May 2021, it was sold in four states: Georgia (Atlanta, Buford), Virginia (Richmond, Tysons), North Carolina (Charlotte, Raleigh), and South Carolina (Charleston, Myrtle Beach), and had 52 specialty stores and 400 retail outlets. While US sales stopped on 29 November 2021 due to a patent lawsuit, they may resume in the near future. As IQOS distribution will likely expand in the future throughout the US, surveillance systems are needed to inform local and national regulatory efforts. Key decision-driving factors for IQOS expansion likely include: 1) general market factors such as larger population/market size and higher median household income; 2) specific IQOS target market factors such as higher consumer spending and smoker prevalence; and 3) more lenient tobacco control context (e.g. cigarette excise taxes, smoke-free policies, state cessation/prevention funding). Likely targets for expansion are markets in Nashville, Tennessee; St. Louis, Missouri; and Louisville, Kentucky. Public health surveillance efforts should monitor IQOS market expansion (e.g. new markets, online direct-toconsumer sales) and IQOS marketing activities (e.g. advertisements, direct marketing, social media, point-of-sale promotions, product trials).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.